[go: up one dir, main page]

KR20110036191A - Method for preparing active piperidine compound by optical separation - Google Patents

Method for preparing active piperidine compound by optical separation Download PDF

Info

Publication number
KR20110036191A
KR20110036191A KR1020090093724A KR20090093724A KR20110036191A KR 20110036191 A KR20110036191 A KR 20110036191A KR 1020090093724 A KR1020090093724 A KR 1020090093724A KR 20090093724 A KR20090093724 A KR 20090093724A KR 20110036191 A KR20110036191 A KR 20110036191A
Authority
KR
South Korea
Prior art keywords
compound
formula
added
chlorophenyl
vii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1020090093724A
Other languages
Korean (ko)
Other versions
KR101146009B1 (en
Inventor
김문식
백두종
Original Assignee
동인화학 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동인화학 주식회사 filed Critical 동인화학 주식회사
Priority to KR1020090093724A priority Critical patent/KR101146009B1/en
Publication of KR20110036191A publication Critical patent/KR20110036191A/en
Application granted granted Critical
Publication of KR101146009B1 publication Critical patent/KR101146009B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

본 발명은 하기화학식 (Ⅱ)의 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘의 제조 방법에 관한 것으로서, 더욱 상세하게는 (±)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘-1-일-R(Ⅲ)화합물을 종전의 공지 방법과는 다른 방법으로 제조하여 이를 광학 활성 분리제를 이용 고순도, 고수율로 광학 분리를 한 후, 일반적인 방법으로 보호기 (R)을 제거하여 고 광학 순도의 목적화합물 (Ⅱ)을 얻는 제조방법에 관한 것이다.The present invention relates to a method for preparing (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidine of the following general formula (II), more specifically (±) -4- [(4-Chlorophenyl) -2-pyridylmethoxy] piperidin-1-yl-R (III) compound was prepared by a method different from the conventionally known methods, and was prepared using an optically active separating agent. After the optical separation in the yield, the protective group (R) is removed by a general method to obtain a target compound (II) of high optical purity.

Figure 112009060564329-PAT00001
Figure 112009060564329-PAT00001

Figure 112009060564329-PAT00002
Figure 112009060564329-PAT00002

상기 식에서, Where

R은 아세틸기, 벤조일기, 벤질기 등의 아미노 보호기이다.R is amino protecting groups, such as an acetyl group, a benzoyl group, and a benzyl group.

Description

광학 분리에 의한 활성 피페리딘 화합물의 제조방법{Process for the preparation of active piperidine compounds by optical isolation}Process for the preparation of active piperidine compounds by optical isolation

본 발명은 항히스타민 활성 및 항알레르기 활성이 우수한 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리디노 부탄산 (Ⅰ)의 벤젠 설폰산 염 또는 벤조산 염의 핵심 중간체인 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘(Ⅱ)의 새로운 제조방법에 관한 것이다.The present invention provides a key intermediate of the benzene sulfonic acid salt or benzoic acid salt of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidino butanoic acid (I), which has excellent antihistamine activity and antiallergic activity. A novel process for the preparation of phosphorus (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidine (II).

본 발명은 공지된 제조방법보다 화학식 (Ⅱ) 화합물을 고순도로 보다 용이하게 제조할 수 있음을 특징으로 한다.The present invention is characterized in that the compound of formula (II) can be produced more easily and with higher purity than a known production method.

Figure 112009060564329-PAT00003
Figure 112009060564329-PAT00003

상기화학식 (Ⅰ)로 표시되는 베포타스틴(bepotastine)은 화학명이 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리디노 부탄산의 벤젠 설폰산 염 또는 벤조산 염이며, 강력한 항히스타민 활성 및 항알레르기 활성을 나타낸다. Bepotastine represented by the formula (I) is a benzene sulfonic acid salt or benzoic acid having a chemical name of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidino butanoic acid. Salt, and exhibits strong antihistamine activity and antiallergic activity.

종전의 제조방법으로는 미국특허 제4929638호, 유럽특허 제335586, 949260호 등이 있으며, 특히, 일본 공개특허 평 2-25465호는 베포타스틴을 라세믹체 화합물로서 최초로 개시하였으며 일본 특허 공개 제2000-198784호에는 라세믹체 화합물 (Ⅱ)를 광학활성 프로피온산 화합물 (Ⅳ) 또는 광학활성 N-아실-아미노산을 작용시키고 생성된 2 종의 부분입체 이성질체 염을 용해도 차이를 이용하여 난용성의 부분입체 이성질체 염을 분리 채취하고, 이어서 이 염을 분해하여 얻어진 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘에 화학식 (Ⅴ)로 표시되는 할로겐산 에스터를 작용시켜 유리 베포타스틴 (Ⅵ)을 얻고, 이를 가수분해하여 (Ⅰ) 화합물을 얻은 후, 다시 벤젠설폰산 또는 벤조산과 염 형성 반응을 시켜 상기화학식 (Ⅰ)로 표시되는 광학활성 피페리딘 화합물 (Ⅰ)의 벤젠설폰산 염 또는 벤조산 염의 제조방법 에 관한 것이다.Conventional manufacturing methods include US Pat. No. 4,953,638, European Patent No. 335586, 949260, and the like. In particular, Japanese Patent Application Laid-Open No. 2-25465 discloses bepotastine as a racemic compound for the first time. -198784 discloses a racemic compound (II) which reacts with an optically active propionic acid compound (IV) or an optically active N-acyl-amino acid and generates two types of diastereomeric salts using different solubility solubility diastereomers. The salt is separated and the halogen acid ester represented by the formula (V) is applied to (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidine obtained by decomposing the salt. To obtain free bepotastine (VI), and hydrolyze it to obtain compound (I), followed by further salt formation reaction with benzenesulfonic acid or benzoic acid to give an optically active piperidine compound represented by the above formula (I) Ⅰ) It relates to a process for preparing benzenesulfonic acid salts or benzoic acid salts.

Figure 112009060564329-PAT00004
Figure 112009060564329-PAT00004

Figure 112009060564329-PAT00005
Figure 112009060564329-PAT00005

Figure 112009060564329-PAT00006
Figure 112009060564329-PAT00006

상기 식중 R은 메틸기, 에틸기 등의 저급 알킬기를 나타내고, W는 할로겐 원 자 등의 이탈기 또는 메탄술포닐 옥시기, p-톨루엔 술포닐옥시기 등의 반응성 에스터기를 나타내며, Y는 수소원자 또는 할로겐 원자이고, Z는 저급알콕시기를 나타낸다.In the above formula, R represents a lower alkyl group such as methyl group or ethyl group, W represents leaving group such as halogen atom or reactive ester group such as methanesulfonyl oxy group, p-toluene sulfonyloxy group, and Y represents hydrogen atom or halogen atom And Z represents a lower alkoxy group.

그러나 상기와 같은 종래방법은 반응공정이 까다롭고, 복잡하며 순도 또한 바람직하지 못하였다.However, the conventional method as described above is difficult to react, complicated and purity is also undesirable.

본 발명은 반응공정을 더욱 간소화하고 고순도의 목적물 (Ⅱ) 화합물을 얻기 위함이다.The present invention is to further simplify the reaction process and to obtain a high purity target compound (II).

본 발명자들은 공지된 방법에 의해 광학적으로 분할된 화학식 (Ⅶ) 화합물을 화학식 (Ⅷ) 화합물과 축합시켜 광학활성체인 화학식 (Ⅲ) 화합물을 얻거나 화학식 (Ⅶ)의 라세믹 중간체를 화학식 (Ⅷ) 화합물과 축합시켜 화학식 (Ⅲ) 라세믹 화합물을 얻은 후, 이 화합물을 광학활성 분리제인 R-(-)-10-캄포설폰산 또는 (-)-디벤조일-D-타르타릭산을 이용하여 디아스테레오머성 염을 형성한 후, 적절한 용매를 이용하여 광학 분리하는 방법에 의해 광학 순도 및 화학적 순도가 높은 화학식 (Ⅱ)의 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘을 간편하게 제조하는 방법을 제공하는데 그 목적이 있다.The present inventors condensed the compound of formula (VII) optically divided by a known method with a compound of formula (VII) to obtain a compound of formula (III) which is an optically active compound or a racemic intermediate of formula (VII). After condensation with a compound to obtain a racemic compound of formula (III), the compound was subjected to dia using R-(-)-10-camphorsulfonic acid or (-)-dibenzoyl-D-tartaric acid as an optically active separating agent. (S) -4-[(4-chlorophenyl) -2-pyridylmethene of formula (II) having high optical purity and chemical purity by the method of optical separation using a suitable solvent after forming a stereomeric salt. It is an object of the present invention to provide a method for easily preparing oxy] piperidine.

상기의 본 발명은 반응공정이 매우 간편하고, 고순도로 목적물을 얻을 수 있다는 장점이 있다.The present invention described above has the advantage that the reaction process is very simple, and the target product can be obtained with high purity.

본 발명은 하기 반응공정 1에 나타낸 바와 같이, 공지의 방법, Tetrahedron Letters vol 37, No 32, pp 5675-5678 (1996): (S)-"Carbinoxamine의 부제합성"과 Bull.Chem.Soc.Jpn,. Vol 60, pp 2651-2655 (1987) "알파-아릴-2-피리딜메탄올의 제조"에서 제시한 바와 같이 화학식 (Ⅶ) 화합물을 제조한 후, (Ⅶ) 화합물을 화학식 (Ⅷ) 화합물과 축합시켜 화학식 (Ⅲ) 화합물을 제조하고 일반적인 방법에 의해 보호기를 제거하여 목적하는 중간체 (Ⅱ) 화합물을 제조한다. The present invention provides a well-known method, Tetrahedron Letters vol 37, No 32, pp 5675-5678 (1996): (S)-"Subsynthesis of Carbinoxamine" and Bull. Chem. Soc. Jpn ,. Vol 60, pp 2651-2655 (1987) After the preparation of the compound of formula (VIII) as shown in "Preparation of alpha-aryl-2-pyridylmethanol", the compound (v) is condensed with the compound of formula (VIII) To prepare the compound of formula (III) and to remove the protecting group by the general method to produce the desired intermediate (II) compound.

[반응공정 1]                                 [Reaction Process 1]

Figure 112009060564329-PAT00007
Figure 112009060564329-PAT00007

상기 식에서, R은 아세틸, 벤조일, 벤질기이며,Wherein R is an acetyl, benzoyl, benzyl group,

X는 할로겐 즉 불소, 염소, 취소, 요오드이거나 알킬 혹은 아릴설포닐옥시기이다.X is halogen, fluorine, chlorine, cancelled, iodine or an alkyl or arylsulfonyloxy group.

좀더 상세하게 설명을 하면 화학식 (Ⅶ) 화합물을 화학식 (Ⅷ) 화합물과 반응시 톨루엔, 디옥산, 크실렌, 메틸이소부틸케톤 혹은 디메틸포름아미드 등과 같은 유기용매를 사용하여 80-140 ℃ 온도, 바람직하게는 100-140 ℃, 더욱 바람직 하기로는 120-140 ℃에서, 예를 들면 소디움카보네이트, 포타시움카보네이트, 중조, 소디움바이카보네이트 등과 같은 알카리금속카보네이트나 바이카보네이트의 산수용체 존재하 축합 반응을 진행시켜 화합물 (Ⅲ)을 얻고, 하기와 같은 일반적인 방법으로 보호기 (R)을 제거하여 화합물 (Ⅱ)를 얻는다.In more detail, when the compound of formula (V) is reacted with the compound of formula (V), an organic solvent such as toluene, dioxane, xylene, methyl isobutyl ketone or dimethylformamide may be used at a temperature of 80-140 ° C., preferably Is condensed at 100-140 ° C., more preferably 120-140 ° C., in the presence of an acid acceptor of an alkali metal carbonate or bicarbonate such as, for example, sodium carbonate, potassium carbonate, sodium bicarbonate, sodium bicarbonate, etc. (III) is obtained and the protecting group (R) is removed by the following general method to obtain compound (II).

즉, 이렇게 얻은 (Ⅲ) 화합물의 R이 벤질일 경우, 접촉환원법에 의해 벤질기를 절단한다.That is, when R of the compound (III) thus obtained is benzyl, the benzyl group is cleaved by the catalytic reduction method.

이때 사용하는 촉매는 팔라디움, 풀라티늄 등의 금속 촉매를 사용하거나 일반적인 벤질기 제거방법을 사용하여 보호기를 제거한다.At this time, the catalyst used may be removed by using a metal catalyst such as palladium, palladium, or a common benzyl group removal method.

R이 아세틸 혹은 벤조일일 경우, 염산 혹은 황산과 같은 무기산 수용액 6-10 N농도를 이용하여 환류하에 2-20 시간 동안, 바람직하기로는 6-14 시간 동안 환류하여 보호기를 제거한다.When R is acetyl or benzoyl, the protecting group is removed by refluxing for 2-20 hours, preferably 6-14 hours, under reflux using an aqueous 6-10 N concentration of an inorganic acid solution such as hydrochloric acid or sulfuric acid.

반응액을 유기용매 즉 에테르, 에틸아세테이트, 벤젠, 톨루엔, 크실렌 등과 같은 유기용매로 세척해준 후 진한 암모니아수, 소디움 혹은 포타시움 하이드록사이드 같은 강알카리 용액으로 알카리화 한 후 유기 용매로 추출해준다.The reaction solution is washed with an organic solvent such as ether, ethyl acetate, benzene, toluene, xylene, and the like, and then alkalinized with a strong alkali solution such as concentrated ammonia water, sodium or potassium hydroxide and extracted with an organic solvent.

이때 유기용매는 클로로포름, 메틸렌클로라이드, 벤젠, 크실렌, 톨루엔, 에틸아세테이트 등의 용매로 추출하여 화합물 (Ⅱ)를 얻는다.At this time, the organic solvent is extracted with a solvent such as chloroform, methylene chloride, benzene, xylene, toluene, ethyl acetate and the like to obtain compound (II).

또 다른 공정으로, 하기 반응공정 2에 나타낸 바와 같이, 상기 화학식 1 화합물의 공지 출발물질 제조방법의 참고문헌에서 제조방법을 제시한 하기 화학식 (Ⅶ) 화합물의 라세믹체 (Ⅶ') 화합물을 염화티오닐 클로라이드로 염소화시킨 후, 얻어진 화학식 (Ⅸ) 화합물에 화학식 (Ⅷ) 화합물을 축합시킨 다음, 얻어진 (±)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘-1-일-R(Ⅲ) 라세믹 혼합물을 광학 활성 분리제인 R-(-)-10-캄포설폰산 또는 (-)-디벤조일 타르타릭산을 반응시켜 고수율, 고순도로 라세믹체 혼합물 중에서 (S)체만을 광학 분리한 후, 일반적인 방법으로 보호기 (R)을 제거하여 구조식 (Ⅱ) 화합물을 제조한다.In another process, as shown in Reaction Step 2, a racemic compound (VII ') of the compound of formula (VII) After chlorination with onyl chloride, the compound of formula (V) is condensed to the obtained compound of formula (VII), and then (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidine- is obtained. The 1-yl-R (III) racemic mixture was reacted with R-(-)-10-camphorsulfonic acid or (-)-dibenzoyl tartaric acid as an optically active separating agent in a racemic mixture in high yield, high purity ( After optical separation of only the S) body, the protecting group (R) is removed in a general manner to prepare the compound of formula (II).

[반응공정 2][Reaction Process 2]

Figure 112009060564329-PAT00008
Figure 112009060564329-PAT00008

상기 식에서, R은 위에서 정의한 바와 같으며, X는 하이드록실기이다.Wherein R is as defined above and X is a hydroxyl group.

상기 반응공정 2를 좀더 상세히 설명하면, 화학식 (Ⅶ)의 라세믹 화합물(Ⅶ')을 티오닐클로라이드, 삼브롬화인, 오브롬화인, 포스포러스옥시클로라이드 등의 할로겐화제로 할로겐화한 후, 얻어진 (Ⅶ) 화합물을 (Ⅷ) 화합물과 축합 시킨다.In more detail, the reaction step 2 is obtained by halogenating a racemic compound of formula (VII) with a halogenating agent such as thionyl chloride, phosphorus tribromide, phosphorus obromide, phosphorus oxychloride, ) Is condensed with the compound (iii).

본 반응시 톨루엔, 디옥산, 크실렌, 메틸이소부틸케톤 혹은 디메틸포름아미드 등과 같은 유기용매를 사용하거나 용매 없이 80-140 ℃, 바람직하기로는 100-140 ℃, 더욱 바람직하기로는 120-140 ℃에서, 예를 들면 소디움카보네이트, 포타시움카보네이트, 중조, 소디움바이카보네이트 등과 같은 알카리금속카보네이트나 바이카보네이트의 산수용체 존재하 축합 반응을 진행시켜 화합물 (Ⅱ)를 얻는다.In the reaction, using an organic solvent such as toluene, dioxane, xylene, methyl isobutyl ketone or dimethylformamide, or without solvent, at 80-140 ℃, preferably 100-140 ℃, more preferably 120-140 ℃, For example, compound (II) is obtained by conducting a condensation reaction in the presence of an acid acceptor of an alkali metal carbonate or bicarbonate such as sodium carbonate, potassium carbonate, sodium bicarbonate and sodium bicarbonate.

이렇게 얻은 화합물 (Ⅱ)를 아세톤 용매하에서 R-(-)-10-캄포설폰산 또는 (-)-디벤조일 타르타릭산과 같은 광학적 활성을 갖는 산으로 라세믹 화합물을 염화 시킨 후, 일정한 광학적 회전을 나타내는 생성물이 얻어질 때까지 상기 염을 연속적으로 재결정화 하고 염기에 의해 그 염으로부터 좌회전성 이성질체를 방출시킴으로써, 목적화합물로 우수한 순도를 갖는 화학식 (Ⅱ) 화합물을 얻는다.Compound (II) thus obtained is chlorinated with a racemic compound with an acid having optical activity such as R-(-)-10-camphorsulfonic acid or (-)-dibenzoyl tartaric acid in acetone solvent, followed by constant optical rotation. By continuously recrystallizing the salts until the product indicated is obtained and releasing left-rotating isomers from the salts with a base, the compound of formula (II) having excellent purity as the target compound is obtained.

이렇게 얻어진 화학식 (Ⅱ) 염 화합물을 적절한 유기용매 중에서 추가로 재결정화시켜 바람직하게는 수율이 60-80 %이고, 광학 순도가 높은 화합물 (Ⅱ)의 R-(-)-10-캄포설폰산 염 또는 (-)-디벤조일 타르타릭산 염을 제조한다.The thus obtained formula (II) salt compound is further recrystallized in a suitable organic solvent, preferably R-(-)-10-camphorsulfonic acid salt of compound (II) having a yield of 60-80% and high optical purity. Or (-)-dibenzoyl tartaric acid salt.

광학적 순도는 적어도 약 95-99.9 %, 바람직하게는 약 98-99.9 %이다.Optical purity is at least about 95-99.9%, preferably about 98-99.9%.

바람직한 공용매는 디메틸 포름 아미드, 디메틸설폭시드, 톨루엔, 헵탄, 디메틸아세트아미드로 구성된 군에서 선택된다.Preferred cosolvents are selected from the group consisting of dimethyl formamide, dimethyl sulfoxide, toluene, heptane, dimethylacetamide.

바람직한 산수용체는 염기이다.Preferred acid acceptors are bases.

그 정의는 상기에서 제시한 바와 같으며 사용몰수는 1-4 배몰수이다.The definition is as set forth above and the number of moles used is 1-4 times the number of moles.

이상에서 설명한 바를, 다음의 실시예에 의거하여 더욱 상세히 설명하겠는바, 본 발명이 이에 한정되는 것은 아니다.The bar described above will be described in more detail based on the following examples, but the present invention is not limited thereto.

[[ 실시예Example ]]

( 실시예 1) 4-하이드록시-1-벤조일 피페리딘의 제조 (Example 1) Preparation of 4-hydroxy-1-benzoyl-piperidine

디클로로메탄 1,200 ml에 소디움보로하이드라이드 5.5 g을 가하고 실온에서 교반하면서 1-벤조일-4-피페리딘 24 g을 디클로로메탄 80 ml에 가해 용해한 후, 상기온도를 유지하면서 서서히 적가한다.5.5 g of sodium borohydride is added to 1,200 ml of dichloromethane, and 24 g of 1-benzoyl-4-piperidine is added to 80 ml of dichloromethane while stirring at room temperature, followed by dropwise addition while maintaining the above temperature.

완전히 가하고 나서 실온으로 온도를 상승시킨 후, 동일 온도에서 6 시간 동안 교반한다.After complete addition, the temperature is raised to room temperature and then stirred at the same temperature for 6 hours.

반응이 완료된 것을 확인한 후 포화 중조수용액 1,200 ml에 서서히 가해주고나서 동일 온도에서 10 분간 교반한다.After confirming that the reaction was completed, slowly added to 1,200 ml of saturated aqueous sodium bicarbonate solution and stirred for 10 minutes at the same temperature.

층분리를 하여 유기층을 증류수 500 ml로 세척하고 무수 황산 마그네슘 5 g으로 건조한 후 여과한다.The layers were separated and the organic layer was washed with 500 ml of distilled water, dried over 5 g of anhydrous magnesium sulfate, and filtered.

여액을 감압에 이해 제거하면 오일상의 표제 목적화합물 20 g (수율 82 %)을 얻는다.The filtrate was removed under reduced pressure to give 20 g (yield 82%) of the title compound as an oil.

1H NMR (CDCl3) : δ 1.96(4H, -CH2-), 2.24(4H, -CH2-), 3.44(1H), 7.44(2H, 방향핵), 7.51(1H, 방향핵), 7.95(2H, 방향핵)1 H NMR (CDCl 3): δ 1.96 (4H, -CH 2-), 2.24 (4H, -CH 2-), 3.44 (1H), 7.44 (2H, aromatic core), 7.51 (1H, aromatic core), 7.95 (2H, Direction nucleus)

( 실시예 2) 4-하이드록시-1-아세틸 피페리딘의 제조 ( Example 2) Preparation of 4-hydroxy-1-acetyl piperidine

디클로로메탄 50 ml에 소디움보로하이드라이드 0.69 g을 가하고 실온에서 1-아세틸-4-피리돈 0.9 ml을 가하고 약 10 시간 동안 교반한다.Add 0.69 g of sodium borohydride to 50 ml of dichloromethane, add 0.9 ml of 1-acetyl-4-pyridone at room temperature and stir for about 10 hours.

반응이 완료된 후 반응액을 포화 중조수용액 50 ml에 가하고 10 분간 교반한다.After the reaction was completed, the reaction solution was added to 50 ml of saturated aqueous sodium bicarbonate solution and stirred for 10 minutes.

디클로로메탄 100 ml로 2 회 추출한다.Extract twice with 100 ml of dichloromethane.

유기층을 정제수 50 ml로 2 회 세척한 후 무수 망초 5 g으로 건조한다.The organic layer was washed twice with 50 ml of purified water and dried over 5 g of dry forget-me-not.

여과를 하고 여액을 감압에 의해 제거하여 상기 표제 목적화합물 0.8 g (수율 86.8 %)를 얻는다.Filtration and removal of the filtrate by reduced pressure yielded 0.8 g (86.8%) of the title compound.

1H NMR (CDCl3) : δ 1.65(4H, -CH2-), 2.0(1H, -OH), 2.02(3H, -CH3), 3.34(4H, -CH2-)1 H NMR (CDCl 3): δ 1.65 (4H, -CH 2-), 2.0 (1H, -OH), 2.02 (3H, -CH 3), 3.34 (4H, -CH 2-)

( 실시예 3) 4-브로모-1-벤조일 피페리딘의 제조 (Example 3) Preparation of 4-bromo-1-benzoyl-piperidine

4-하이드록시-1-벤조일 피페리딘 20 g을 벤젠 80 ml에 가해 용해한다.20 g of 4-hydroxy-1-benzoyl piperidine are added to 80 ml of benzene and dissolved.

삼브롬화 인 11 ml을 서서히 가하고 가열하여 3 시간 동안 환류한다.11 ml of phosphorus tribromide are slowly added and heated to reflux for 3 hours.

반응이 완료된 것을 확인하고 실온으로 냉각한다.Confirm that the reaction is complete and cool to room temperature.

반응액에 정제수 200 ml을 가하고 실온에서 10 분간 교반한 후 층분리를 한 다음, 유기층을 취하여 정제수 50 ml로 2 회 세척한다.200 ml of purified water was added to the reaction solution, the mixture was stirred at room temperature for 10 minutes, followed by layer separation. The organic layer was taken out and washed twice with 50 ml of purified water.

유기층을 무수 망초로 건조한 후 여과한다.The organic layer is dried over anhydrous forget-me-not and filtered.

여액을 진공으로 제거하여 오일상의 상기 표제 목적화합물 11.6 g(수율 45 %)을 얻는다.The filtrate is removed in vacuo to give 11.6 g (45% yield) of the title compound as an oil.

1H NMR (CDCl3) : δ 1.96(4H, -CH2-), 3.34(4H, -CH2-), 3.44(1H), 7.44(2H, 방향핵), 7.51(1H), 7.95(2H)1 H NMR (CDCl 3): δ 1.96 (4H, -CH 2-), 3.34 (4H, -CH 2-), 3.44 (1H), 7.44 (2H, aromatic nucleus), 7.51 (1H), 7.95 (2H)

( 실시예 4) 4-브로모-1-벤질피페리딘의 제조 (Example 4) Preparation of 4-bromo-1-benzyl piperidine

4-하이드록시-1-벤질피페리딘 0.83 g을 벤젠 4 ml에 가해 용해한 후 삼브로모인 1.43 g을 가한다.0.83 g of 4-hydroxy-1-benzylpiperidine is added to 4 ml of benzene and dissolved, followed by 1.43 g of tribromoin.

가온하여 5 시간 동안 환류한 다음 실온으로 냉각한다.Warm to reflux for 5 hours and then cool to room temperature.

반응액에 냉수 5 ml을 가하고 5 분간 교반한 다음 진한 암모니아수로 강하게 알카리화한다. 5 ml of cold water is added to the reaction mixture, which is stirred for 5 minutes, followed by strong alkaline with concentrated ammonia water.

층분리를 하여 유기층을 취하고 정제수 2 ml로 2 회 세척한다.The layers are separated and the organic layer is taken and washed twice with 2 ml of purified water.

유기층을 무수 망초로 건조하고 여과 후 여액을 감압에 의해 제거하여 상기 표제 목적화합물 0.35 g (수율 32 %)을 얻는다.The organic layer is dried over anhydrous forget-me-not, filtered and the filtrate is removed by reduced pressure to give 0.35 g (yield 32%) of the title compound.

1H NMR (CDCl3) : δ 1.96(4H, -CH2-), 3.24(4H, -CH2-), 3.44(1H), 3.62(2H, -CH2-), 7.06(2H, 방향핵), 7.07(1H, 방향핵), 7.14(2H, 방향핵)1 H NMR (CDCl3): δ 1.96 (4H, -CH2-), 3.24 (4H, -CH2-), 3.44 (1H), 3.62 (2H, -CH2-), 7.06 (2H, aromatic nucleus), 7.07 (1H) , Direction nucleus), 7.14 (2H, direction nucleus)

( 실시예 5) 4-브로모-1-아세틸피페리딘의 제조 (Example 5) Preparation of 4-Bromo-1-Acetyl-piperidine

4-하이드록시-1-아세틸피페리딘 0.83 g을 벤젠 4 ml에 가해 용해한 후 삼브로모인 1.43 g을 가한다.0.83 g of 4-hydroxy-1-acetylpiperidine is added to 4 ml of benzene to dissolve, followed by 1.43 g of tribromoin.

가온하여 5 시간 동안 환류한 다음 실온으로 냉각한다.Warm to reflux for 5 hours and then cool to room temperature.

반응액에 냉수 5 ml을 가하고 5 분간 교반한 다음 진한 암모니아수로 강하게 알카리화한다. 5 ml of cold water is added to the reaction mixture, which is stirred for 5 minutes, followed by strong alkaline with concentrated ammonia water.

층분리를 하여 유기층을 취하고 정제수 2 ml로 2 회 세척한다.The layers are separated and the organic layer is taken and washed twice with 2 ml of purified water.

유기층을 무수 망초로 건조하고 여과 후 여액을 감압에 의해 제거하여 상기 표제 목적화합물 0.42 g (수율 35 %)을 얻는다.The organic layer was dried over anhydrous forget-me-not, filtered and the filtrate was removed by reduced pressure to give 0.42 g (yield 35%) of the title compound.

1H NMR (CDCl3) : δ 1.96(4H, -CH2-), 2.03(3H), 3.24(4H, -CH2-), 3.44(1H)1 H NMR (CDCl 3): δ 1.96 (4H, -CH 2-), 2.03 (3H), 3.24 (4H, -CH 2-), 3.44 (1H)

( 실시예 6) 알파-p-클로로페닐-2-피리딘 클로로 메탄의 제조 ( Example 6) Preparation of alpha-p-chlorophenyl-2-pyridine chloromethane

알파-p-클로로페닐-2-피리딘 메탄올 8 g을 벤젠 54 ml에 가하고 용해한 다음 냉각한다.8 g of alpha-p-chlorophenyl-2-pyridine methanol are added to 54 ml of benzene, dissolved and cooled.

이용액에 티오닐클로라이드 6 ml을 가하고 상온에서 하룻밤 교반한다.6 ml of thionyl chloride is added to the solution, and the mixture is stirred overnight at room temperature.

반응이 완료된 후 10 % 암모니아수 50 ml을 가해 알카리화 한 다음 층분리를 한다.After the reaction was completed, 50 ml of 10% aqueous ammonia was added to the mixture, followed by layer separation.

유기층을 무수 망초로 건조하고 여과하여 여액을 감압에 의해 제거한다.The organic layer is dried over anhydrous forget-me-not and filtered to remove the filtrate by reduced pressure.

상기 표제 목적화합물 6 g (수율 70 %)를 얻는다.6 g (yield 70%) of the title compound are obtained.

1H NMR (CDCl3) : δ 6.04(1H), 7.18(1H), 7.20(2H), 7.27(2H), 7.50(1H), 7.67(1H), 8.61(1H)1 H NMR (CDCl 3): δ 6.04 (1H), 7.18 (1H), 7.20 (2H), 7.27 (2H), 7.50 (1H), 7.67 (1H), 8.61 (1H)

( 실시예 7) 알파-[(p-클로로페닐-2-피리딘)메톡시]-1-벤조일-4-피페리딘의 제조 Example 7 alpha - [(p- chlorophenyl-2-pyridinyl) methoxy] Preparation of 1-benzoyl-4-piperidine

4-하이드록시-1-벤조일 피페리딘 0.55 g을 톨루엔 3 ml에 가하고 금속 소디움 62 mg을 실온에서 조심스럽게 가한다.0.55 g of 4-hydroxy-1-benzoyl piperidine is added to 3 ml of toluene and 62 mg of metal sodium are carefully added at room temperature.

완전히 가하고 나서 금속소디움이 모두 용해될 때까지 가열 교반한다.After complete addition, the mixture is heated and stirred until all of the metal sodium is dissolved.

그리고나서 알파-p-클로로페닐-2-피리딘 클로로 메탄 0.74 g을 톨루엔 3 ml에 용해하여 60 분간에 걸쳐 조심스럽게 서서히 가해준다.Then 0.74 g of alpha-p-chlorophenyl-2-pyridine chloromethane is dissolved in 3 ml of toluene and carefully added slowly over 60 minutes.

모두 가하고 나서 36 시간 동안 환류 교반한 다음 실온으로 냉각한다.After the addition, the mixture was stirred under reflux for 36 hours and then cooled to room temperature.

정제수 5 ml을 가하고 희염산 3 ml를 가해 세척해 준다.5 ml of purified water is added and 3 ml of dilute hydrochloric acid is added for washing.

층분리를 하여 유기층을 취하고, 무수 망초 0.1 g으로 건조하고 여과하여 유기용매를 감압에 의해 제거한다.The organic layer was separated by layer separation, dried over 0.1 g of anhydrous manganese, filtered and the organic solvent was removed by reduced pressure.

상기 표제 목적화합물 0.9 g (수율 82.6 %)를 얻는다.0.9 g (yield 82.6%) of the title compound is obtained.

1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 3.34(4H, -CH2-), 5.41(1H), 7.13(2H, 방향핵), 7.18(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1H NMR (CDCl3): δ 1.63 (4H, -CH2-), 2.85 (1H), 3.34 (4H, -CH2-), 5.41 (1H), 7.13 (2H, direction nucleus), 7.18 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)

( 실시예 8) (±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘의 제조 (Example 8) (±) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of benzyl piperidin-

4-하이드록시-1-벤질피페리딘 2.4 g, 소디움 카보네이트 2.7 g, 메틸이소부틸케톤 32 ml을 가하고 1 시간 동안 환류한다.2.4 g of 4-hydroxy-1-benzylpiperidine, 2.7 g of sodium carbonate and 32 ml of methyl isobutyl ketone are added and refluxed for 1 hour.

알파-p-클로로페닐-2-피리딘 클로로메탄 6 g을 메틸이소부틸 케톤 5 ml에 가해 용해 후 상기 혼합액에 90 분간에 걸쳐 적가해 준다.6 g of alpha-p-chlorophenyl-2-pyridine chloromethane is added to 5 ml of methyl isobutyl ketone and dissolved and added dropwise to the mixed solution over 90 minutes.

적가가 끝난 후 36 시간 동안 환류한다.It is refluxed for 36 hours after the addition.

실온으로 냉각 후 용매를 감압으로 제거하고 디클로로메탄 50 ml을 가하고 정제수 30 ml로 세척한다.After cooling to room temperature, the solvent was removed under reduced pressure, 50 ml of dichloromethane was added and washed with 30 ml of purified water.

무수 망초로 건조한 후 여과하고 여액을 감압에 의해 제거한다.Dry over anhydrous forget-me-not, filter and remove the filtrate by reduced pressure.

상기 표제 목적화합물 4 g (수율 80 %)을 얻는다.4 g (yield 80%) of the title compound are obtained.

1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 2.24(4H, -CH2-), 5.41 (1H), 7.06(2H, 방향핵), 7.14(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1 H NMR (CDCl 3): δ 1.63 (4H, -CH2-), 2.85 (1H), 2.24 (4H, -CH2-), 5.41 (1H), 7.06 (2H, direction nucleus), 7.14 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)

( 실시예 9) (±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘의 제조 (Example 9) (±) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of acetyl piperidine

4-하이드록시-1-아세틸피페리딘 2.4 g, 소디움 카보네이트 2.7 g, 메틸이소부틸케톤 32 ml을 가하고 1 시간 동안 환류한다.2.4 g of 4-hydroxy-1-acetylpiperidine, 2.7 g of sodium carbonate and 32 ml of methyl isobutyl ketone are added and refluxed for 1 hour.

알파-p-클로로페닐-2-피리딘 클로로메탄 6 g을 메틸이소부틸 케톤 5 ml에 가해 용해 후 상기 혼합액에 90 분간에 걸쳐 적가해 준다.6 g of alpha-p-chlorophenyl-2-pyridine chloromethane is added to 5 ml of methyl isobutyl ketone and dissolved and added dropwise to the mixed solution over 90 minutes.

적가가 끝난 후 36 시간 동안 환류한다.It is refluxed for 36 hours after the addition.

실온으로 냉각 후 용매를 감압으로 제거하고 디클로로메탄 50 ml을 가하고 정제수 30 ml로 세척한다.After cooling to room temperature, the solvent was removed under reduced pressure, 50 ml of dichloromethane was added and washed with 30 ml of purified water.

무수 망초로 건조한 후 여과하고 여액을 감압에 의해 제거한다.Dry over anhydrous forget-me-not, filter and remove the filtrate by reduced pressure.

상기 표제 목적화합물 4.6 g (수율 80 %)을 얻는다.4.6 g (yield 80%) of the title compound are obtained.

1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.3(3H), 2.85(1H), 3.24(4H, -CH2-), 5.41(1H), 7.06(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1 H NMR (CDCl 3): δ 1.63 (4H, -CH2-), 2.3 (3H), 2.85 (1H), 3.24 (4H, -CH2-), 5.41 (1H), 7.06 (2H, aromatic nucleus), 7.50 ( 1H, Directional Core), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)

( 실시예 10) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘의 제조 (Example 10) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] Preparation of -N- benzoyl piperidine

(s)-4-클로로페닐-2-피리딜 메탄올 5.6 g, 소디움 카보네이트 2.7 g, 메틸이소부틸케톤 16 ml을 가하고 30 분간 환류한 다음, 4-브로모-1-벤조일 피페리딘 3.4 g을 메틸이소부틸케톤 4 ml에 가해 용해시킨 후 상기용액에 90 분간에 걸쳐 적가해 준다.(s) 5.6 g of 4-chlorophenyl-2-pyridyl methanol, 2.7 g of sodium carbonate and 16 ml of methyl isobutyl ketone were added and refluxed for 30 minutes, followed by 3.4 g of 4-bromo-1-benzoyl piperidine. It is added to 4 ml of methyl isobutyl ketone and dissolved, and then added dropwise to the solution over 90 minutes.

완전히 가하고나서 12 시간 동안 환류한다.After complete addition, reflux for 12 hours.

실온으로 냉각 후 디클로로메탄 32 ml을 가하고 10 분간 교반 후 정제수 20 ml로 세척한다.After cooling to room temperature, 32 ml of dichloromethane is added, stirred for 10 minutes, and washed with 20 ml of purified water.

층분리를 하여 유기층을 취하고 무수 망초 0.5 g으로 건조한 다음 여과하고 여액을 감압에 의해 제거한다.The layers are separated and the organic layer is taken, dried over 0.5 g of dry forget-me-not, filtered and the filtrate is removed by reduced pressure.

상기 표제 목적화합물 7.3 g (수율 70 %)을 얻는다.7.3 g (yield 70%) of the title compound are obtained.

1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 3.34(4H, -CH2-), 5.41(1H), 7.13(2H, 방향핵), 7.18(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1H NMR (CDCl3): δ 1.63 (4H, -CH2-), 2.85 (1H), 3.34 (4H, -CH2-), 5.41 (1H), 7.13 (2H, direction nucleus), 7.18 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)

( 실시예 11) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘의 제조 (Example 11) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of benzyl piperidin-

(s)-4-클로로페닐-2-피리딜 메탄올 5.6 g, 소디움 카보네이트 2.7 g, 메틸이소부틸케톤 16 ml을 가하고 30 분간 환류한 다음, 4-브로모-1-벤질 피페리딘 3.2 g을 메틸이소부틸 4 ml에 가해 용해시킨 후 상기용액에 서서히 가해준다.(s) 5.6 g of 4-chlorophenyl-2-pyridyl methanol, 2.7 g of sodium carbonate, and 16 ml of methyl isobutyl ketone were added and refluxed for 30 minutes, followed by 3.2 g of 4-bromo-1-benzyl piperidine. It is added to 4 ml of methyl isobutyl and dissolved, and then slowly added to the solution.

완전히 가하고 나서 12 시간 동안 환류한다.After complete addition, reflux for 12 hours.

실온으로 냉각 후 디클로로메탄 32 ml을 가하고 10 분간 교반한 후 정제수 20 ml을 가한다.After cooling to room temperature, 32 ml of dichloromethane was added, stirred for 10 minutes, and 20 ml of purified water was added thereto.

실온에서 10 분간 교반 후 층분리를 하여 유기층을 취한다.After stirring for 10 minutes at room temperature, the layers are separated and the organic layer is taken.

무수 망초 0.5 g으로 건조 후 여과하여 여액을 감압에 의해 제거한다.After drying with 0.5 g of dry forget-me-not, the filtrate is removed by reduced pressure.

상기 표제 목적화합물 8.0 g (수율 80 %)을 얻는다.8.0 g (yield 80%) of the title compound are obtained.

1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 2.24(4H, -CH2-), 5.41(1H), 7.06(2H, 방향핵), 7.14(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1H NMR (CDCl3): δ 1.63 (4H, -CH2-), 2.85 (1H), 2.24 (4H, -CH2-), 5.41 (1H), 7.06 (2H, direction nucleus), 7.14 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)

( 실시예 12) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘의 제조 (Example 12) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of acetyl piperidine

(s)-4-클로로페닐-2-피리딜 메탄올 5.6 g, 소디움 카보네이트 2.7 g, 메틸이소부틸케톤 16 ml을 가하고 30 분간 환류한 다음, 4-브로모-1-아세틸 피페리딘 5.2 g을 메틸이소부틸 4 ml에 가해 용해시킨 후 상기용액에 서서히 가해준다.(s) 5.6 g of 4-chlorophenyl-2-pyridyl methanol, 2.7 g of sodium carbonate and 16 ml of methyl isobutyl ketone were added and refluxed for 30 minutes, followed by 5.2 g of 4-bromo-1-acetyl piperidine. It is added to 4 ml of methyl isobutyl and dissolved, and then slowly added to the solution.

완전히 가하고 나서 12 시간 동안 환류한다.After complete addition, reflux for 12 hours.

실온으로 냉각 후 디클로로메탄 32 ml을 가하고 10 분간 교반한 후 정제수 20 ml을 가한다.After cooling to room temperature, 32 ml of dichloromethane was added, stirred for 10 minutes, and 20 ml of purified water was added thereto.

실온에서 10 분간 교반 후 층분리를 하여 유기층을 취한다.After stirring for 10 minutes at room temperature, the layers are separated and the organic layer is taken.

무수 망초 0.5 g으로 건조 후 여과하여 여액을 감압에 의해 제거한다.After drying with 0.5 g of dry forget-me-not, the filtrate is removed by reduced pressure.

상기 표제 목적화합물 7.0 g (수율 80 %)을 얻는다.7.0 g (yield 80%) of the title compound are obtained.

1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.3(3H), 2.85(1H), 3.24(4H, -CH2-), 5.41(1H), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1 H NMR (CDCl 3): δ 1.63 (4H, -CH2-), 2.3 (3H), 2.85 (1H), 3.24 (4H, -CH2-), 5.41 (1H), 7.44 (2H, aromatic nucleus), 7.50 ( 1H, Directional Core), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)

( 실시예 13) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘의 제조 (Example 13) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of benzyl piperidin-

(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 44 g을 아세톤 184 ml에 가하고 실온에서 교반한다.44 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine are added to 184 ml of acetone and stirred at room temperature.

R-(-)-10-캄포설폰산 15.4 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.15.4 g of R-(-)-10-camphorsulfonic acid is added to 62 ml of acetone solution to dissolve and then added at 20-25 ° C.

실온에서 1 시간가량 교반한 후 생성된 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 캄포설폰산 염을 냉각하고 결정화한다.After stirring for 1 hour at room temperature, the resulting (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine camphorsulfonic acid salt is cooled and crystallized.

필요하다면 씨딩을 행한다.Seeding is done if necessary.

결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.

이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 23 g (수율 33 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 23 g (yield 33%) of the title compound is obtained.

이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 캄포설폰산 염 56.3 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.56.3 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine camphorsulfonic acid salt was added to 100 ml of dichloromethane and the reaction mixture was stirred for 10 minutes. Stir.

이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.

층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.

유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.

이렇게 하여 상기 표제 목적물을 유상으로 34 g (수율 96 %)을 얻는다.This gives 34 g (96% yield) of the title object as an oil.

1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 2.24(4H, -CH2-), 5.41(1H), 7.06(2H, 방향핵), 7.14(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1H NMR (CDCl3): δ 1.63 (4H, -CH2-), 2.85 (1H), 2.24 (4H, -CH2-), 5.41 (1H), 7.06 (2H, direction nucleus), 7.14 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)

( 실시예 14) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘의 제조 (Example 14) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] Preparation of -N- benzoyl piperidine

(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 45.5 g을 아세톤 184 ml에 가하고 실온에서 교반한다.45.5 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine are added to 184 ml of acetone and stirred at room temperature.

R-(-)-10-캄포설폰산 15.4 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.15.4 g of R-(-)-10-camphorsulfonic acid is added to 62 ml of acetone solution to dissolve and then added at 20-25 ° C.

실온에서 1 시간가량 교반한 후 생성된 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 캄포설폰산 염을 냉각하고 결정화한다.After stirring for 1 hour at room temperature, the resulting (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine camphorsulfonic acid salt is cooled and crystallized.

필요하다면 씨딩을 행한다.Seeding is done if necessary.

결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.

이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 23.6 g (수율 33 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 23.6 g (yield 33%) of the title compound are obtained.

이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 캄포설폰산 염 57.5 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.57.5 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine camphorsulfonic acid salt was added to 100 ml of dichloromethane and the reaction mixture was stirred for 10 minutes. Stir.

이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.

층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.

유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.

이렇게 하여 상기 표제 목적물을 유상으로 35 g (수율 96 %)을 얻는다.This gives 35 g (96% yield) of the title object as an oil.

( 실시예 15) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘의 제조 (Example 15) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of acetyl piperidine

(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 38.6 g을 아세톤 184 ml에 가하고 실온에서 교반한다.38.6 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetyl piperidine are added to 184 ml of acetone and stirred at room temperature.

R-(-)-10-캄포설폰산 15.4 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.15.4 g of R-(-)-10-camphorsulfonic acid is added to 62 ml of acetone solution to dissolve and then added at 20-25 ° C.

실온에서 1 시간가량 교반한 후 생성된 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 캄포설폰산 염을 냉각하고 결정화한다.After stirring for 1 hour at room temperature, the resulting (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetyl piperidine camphorsulfonic acid salt is cooled and crystallized.

필요하다면 씨딩을 행한다.Seeding is done if necessary.

결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.

이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 25.8 g (수율 40 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 25.8 g (40% yield) of the title compound are obtained.

이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 캄 포설폰산 염 25.8 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.25.8 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetyl piperidine camphorsulfonic acid salt was added to 100 ml of dichloromethane and the reaction mixture was stirred for 10 minutes. Stir.

이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.

층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.

유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.

이렇게 하여 상기 목적물을 유상으로 24 g (수율 93 %)을 얻는다.Thus, 24 g (yield 93%) of the target substance is obtained as an oil phase.

1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.3(3H), 2.85(1H), 3.34(4H, -CH2-), 5.41(1H), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1 H NMR (CDCl 3): δ 1.63 (4H, -CH2-), 2.3 (3H), 2.85 (1H), 3.34 (4H, -CH2-), 5.41 (1H), 7.44 (2H, aromatic nucleus), 7.50 ( 1H, Directional Core), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)

( 실시예 16) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘의 제조 (Example 16) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of benzyl piperidin-

(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 45.5 g을 아세톤 184 ml에 가하고 실온에서 교반한다.45.5 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine are added to 184 ml of acetone and stirred at room temperature.

(-)-디벤조일-L-타르타르산-수화물 42 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.42 g of (-)-dibenzoyl-L-tartaric acid-hydrate are added to 62 ml of acetone solution and dissolved, and then added at 20-25 ° C.

실온에서 1 시간가량 교반한 후 생성된 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 (-)-디벤조일-L-타르타르산 염을 냉각하고 결정화한다.After stirring for 1 hour at room temperature, the resulting (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine (-)-dibenzoyl-L-tartaric acid salt Cool and crystallize.

필요하다면 씨딩을 행한다.Seeding is done if necessary.

결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.

이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 30 g (수율 35 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 30 g (yield 35%) of the title compound is obtained.

이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 (-)-디벤조일-L-타르타르산 염 69.2 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.69.2 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine (-)-dibenzoyl-L-tartaric acid salt thus obtained was added to 100 ml of dichloromethane. And the reaction mixture is stirred for 10 minutes.

이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.

층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.

유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.

이렇게 하여 상기 표제 목적물을 유상으로 34.7 g (수율 98 %)을 얻는다.This affords 34.7 g (98% yield) of the title object as oil.

( 실시예 17) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘의 제조 (Example 17) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] Preparation of -N- benzoyl piperidine

(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 45.5 g을 아세톤 184 ml에 가하고 실온에서 교반한다.45.5 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine are added to 184 ml of acetone and stirred at room temperature.

(-)-디벤조일-L-타르타르산-수화물 42 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.42 g of (-)-dibenzoyl-L-tartaric acid-hydrate are added to 62 ml of acetone solution and dissolved, and then added at 20-25 ° C.

실온에서 1 시간가량 교반한 후 생성된(S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 (-)-디벤조일-L-타르타르산-염을 냉각하고 결정화한다.After stirring for 1 hour at room temperature, the resulting (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine (-)-dibenzoyl-L-tartaric acid-salt Cool and crystallize.

필요하다면 씨딩을 행한다.Seeding is done if necessary.

결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.

이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 30.6 g (수율 35 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 30.6 g (yield 35%) of the title compound are obtained.

이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 (-)-디벤조일-L-타르타르산 염 70.5 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.70.5 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine (-)-dibenzoyl-L-tartaric acid salt thus obtained was added to 100 ml of dichloromethane. And the reaction mixture is stirred for 10 minutes.

이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.

층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.

유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.

이렇게 하여 상기 표제 목적물을 유상으로 34.8 g (수율 95 %)을 얻는다.This affords 34.8 g (95% yield) of the title object as oil.

1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.85(1H), 3.34(4H, -CH2-), 5.41(1H), 7.13(2H, 방향핵), 7.18(1H, 방향핵), 7.20(2H, 방향핵), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1H NMR (CDCl3): δ 1.63 (4H, -CH2-), 2.85 (1H), 3.34 (4H, -CH2-), 5.41 (1H), 7.13 (2H, direction nucleus), 7.18 (1H, direction nucleus) , 7.20 (2H, direction nucleus), 7.44 (2H, direction nucleus), 7.50 (1H, direction nucleus), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)

( 실시예 18) (s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘의 제조 (Example 18) (s) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] -N- Preparation of acetyl piperidine

(±)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 38.6 g을 아세 톤 184 ml에 가하고 실온에서 교반한다.38.6 g of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetyl piperidine are added to 184 ml of acetone and stirred at room temperature.

(-)-디벤조일-L-타르타르산-수화물 42 g을 아세톤 용액 62 ml에 가해 용해시킨 후, 20-25 ℃에서 첨가한다.42 g of (-)-dibenzoyl-L-tartaric acid-hydrate are added to 62 ml of acetone solution and dissolved, and then added at 20-25 ° C.

실온에서 1 시간가량 교반한 후 생성된 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 (-)-디벤조일-L-타르타르산-염을 냉각하고 결정화한다.(S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetyl piperidine (-)-dibenzoyl-L-tartaric acid-salt formed after stirring for 1 hour at room temperature Cool and crystallize.

필요하다면 씨딩을 행한다.Seeding is done if necessary.

결정화가 많을 경우 혼합물을 환류하에 가열하고 이어서 25 ℃까지 냉각한다.If there is much crystallization, the mixture is heated to reflux and then cooled to 25 ° C.

이어서 결정을 여과하고 아세톤으로 세척하고 이어서 감압하에 건조한다. 상기 표제 목적화합물 31 g (수율 40 %)을 얻는다.The crystals are then filtered off, washed with acetone and then dried under reduced pressure. 31 g (40% yield) of the title compound is obtained.

이렇게 얻은 (S)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-아세틸 피페리딘 (-)-디벤조일-L-타르타르산 염 31 g을 100 ml의 디클로로메탄에 가하고 반응혼합물을 10 분 동안 교반한다.31 g of (S) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-acetylpiperidine (-)-dibenzoyl-L-tartaric acid salt thus obtained was added to 100 ml of dichloromethane. And the reaction mixture is stirred for 10 minutes.

이어서 70 ml의 정제수에 탄산 칼륨 9.1 g을 녹인 용액을 가한다.A solution of 9.1 g of potassium carbonate dissolved in 70 ml of purified water is then added.

층분리를 하여 유기층을 취하고 수층을 디클로로메탄으로 여러 번에 걸쳐 추출한다.The layers are separated and the organic layer is taken and the aqueous layer is extracted several times with dichloromethane.

유기층을 합하고 진공하에서 농축한다.The organic layers are combined and concentrated in vacuo.

이렇게 하여 상기 표제 목적물을 유상으로 30 g (수율 96.7 %)을 얻는다.This gives 30 g (yield 96.7%) of the title object as an oil.

1H NMR (CDCl3) : δ 1.63(4H, -CH2-), 2.3(3H), 2.85(1H), 3.34(4H, -CH2- ), 5.41(1H), 7.44(2H, 방향핵), 7.50(1H, 방향핵), 7.51(1H), 7.67(1H), 7.95(2H), 8.61(1H)1 H NMR (CDCl 3): δ 1.63 (4H, -CH2-), 2.3 (3H), 2.85 (1H), 3.34 (4H, -CH2-), 5.41 (1H), 7.44 (2H, aromatic nucleus), 7.50 ( 1H, Directional Core), 7.51 (1H), 7.67 (1H), 7.95 (2H), 8.61 (1H)

( 실시예 19) (S)-4-[(4-클로로페닐)-2-피리딜 메톡시] 피페리딘의 제조 (Example 19) (S) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] piperidine Preparation of

(s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤질 피페리딘 39.3 g을 메탄올 300 ml에 가하고 팔라디움 차콜 3 g을 가한다.39.3 g of (s) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzyl piperidine are added to 300 ml of methanol and 3 g of palladium charcoal.

빙초산 5 ml을 같이 혼합하여 교반하면서 수소 가스를 주입시켜 상압정도를 유지하면서 12 시간 교반한다.5 ml of glacial acetic acid are mixed together, hydrogen gas is injected while stirring, and the mixture is stirred for 12 hours while maintaining the atmospheric pressure.

반응이 종료되었음을 확인한 후 여과를 하고 여액을 감압에 의해 제거해 준다.After confirming that the reaction is completed, the filtrate is removed and the filtrate is removed by reduced pressure.

상기 표제 목적화합물 36.6 g (수율 93 %)을 얻는다.36.6 g (93% yield) of the title compound is obtained.

키랄순도 : 100 %Chiral Purity: 100%

1H NMR (CDCL3) : δ 1.63(4H, -CH2-), 2.74(4H, -CH2-), 2.85(1H), 5.41(1H), 7.13(2H), 7.18(1H), 7.20(2H), 7.50(1H), 7.67(1H), 8.61(H)1 H NMR (CDCL3): δ 1.63 (4H, -CH2-), 2.74 (4H, -CH2-), 2.85 (1H), 5.41 (1H), 7.13 (2H), 7.18 (1H), 7.20 (2H), 7.50 (1 H), 7.67 (1 H), 8.61 (H)

( 실시예 20) (S)-4-[(4-클로로페닐)-2-피리딜 메톡시] 피페리딘의 제조 (Example 20) (S) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] piperidine Preparation of

(s)-4-[(4-클로로페닐)-2-피리딜 메톡시]-N-벤조일 피페리딘 40.7 g을 6 N- 염산 300 ml에 가하고 24 시간 동안 환류 교반한다.40.7 g of (s) -4-[(4-chlorophenyl) -2-pyridylmethoxy] -N-benzoyl piperidine are added to 300 ml of 6 N-hydrochloric acid and stirred at reflux for 24 hours.

반응이 종료된 후 진한 암모니아수로 반응액을 알카리화 한 후 클로로포름 500 ml로 3 회 추출한다.After the reaction was completed, the reaction solution was alkalined with concentrated ammonia water and extracted three times with 500 ml of chloroform.

추출액을 무수 망초로 건조하고 여과한 후 여액을 감압에 의해 제거한다.The extract is dried over anhydrous forget-me-not, filtered and the filtrate is removed by reduced pressure.

상기 표제 목적화합물 36.6 g (수율 90 %)을 얻는다.36.6 g (yield 90%) of the title compound are obtained.

키랄순도 : 100 %Chiral Purity: 100%

1H NMR (CDCL3) : δ 1.63(4H, -CH2-), 2.74(4H, -CH2-), 2.85(1H), 5.41(1H), 7.13(2H), 7.18(1H), 7.20(2H), 7.50(1H), 7.67(1H), 8.61(H)1 H NMR (CDCL3): δ 1.63 (4H, -CH2-), 2.74 (4H, -CH2-), 2.85 (1H), 5.41 (1H), 7.13 (2H), 7.18 (1H), 7.20 (2H), 7.50 (1 H), 7.67 (1 H), 8.61 (H)

( 실시예 21) (S)-4-[(4-클로로페닐)-2-피리딜 메톡시] 피페리딘의 제조 (Example 21) (S) -4 - [ (4- chlorophenyl) -2-pyridyl methoxy] piperidine Preparation of

(s)-4-[(4-클로로페닐)-(2-피리딜 메톡시]-N-아세틸 피페리딘 34.5 g을 6 N- 염산 300 ml에 가하고 48 시간 동안 환류 교반한다.34.5 g of (s) -4-[(4-chlorophenyl)-(2-pyridylmethoxy] -N-acetyl piperidine are added to 300 ml of 6 N-hydrochloric acid and stirred at reflux for 48 hours.

반응이 종료된 후 진한 암모니아수로 반응액을 알카리화 한 후 클로로포름 500 ml로 3 회 추출한다.After the reaction was completed, the reaction solution was alkalined with concentrated ammonia water and extracted three times with 500 ml of chloroform.

추출액을 무수 망초로 건조하고 여과한 후 여액을 감압에 의해 제거한다.The extract is dried over anhydrous forget-me-not, filtered and the filtrate is removed by reduced pressure.

상기 표제 목적화합물 27.3 g (수율 90 %)을 얻는다.27.3 g (yield 90%) of the title compound are obtained.

키랄순도 : 100 %Chiral Purity: 100%

1H NMR (CDCL3) : δ 1.63(4H, -CH2-), 2.74(4H, -CH2-), 2.85(1H), 5.41(1H), 7.13(2H), 7.18(1H), 7.20(2H), 7.50(1H), 7.67(1H), 8.61(H)1 H NMR (CDCL3): δ 1.63 (4H, -CH2-), 2.74 (4H, -CH2-), 2.85 (1H), 5.41 (1H), 7.13 (2H), 7.18 (1H), 7.20 (2H), 7.50 (1 H), 7.67 (1 H), 8.61 (H)

Claims (2)

하기 화학식 (Ⅶ) 화합물을 하기 화학식 (Ⅷ) 화합물과 유기용매 및 산수용체 존재하 80-140 ℃에서 축합반응 시켜 하기 화학식 (Ⅲ) 화합물을 얻고, 일반적인 방법으로 하기 화학식 (Ⅲ) 화합물의 보호기 (R)을 제거함을 특징으로 하는 하기 화학식 (Ⅱ) 화합물의 제조방법.The compound of formula (VII) is condensed at 80-140 ° C. in the presence of the compound of formula (VII), an organic solvent and an acid acceptor to obtain a compound of formula (III), and a protecting group of the compound of formula (III) R) is removed, the process for preparing the compound of formula (II).
Figure 112009060564329-PAT00009
Figure 112009060564329-PAT00009
상기 식에서, R은 아세틸, 벤조일, 벤질기이며,Wherein R is an acetyl, benzoyl, benzyl group, X는 할로겐 즉 불소, 염소, 취소, 요오드이거나 알킬 혹은 아릴설포닐옥시기이다.X is halogen, fluorine, chlorine, cancelled, iodine or an alkyl or arylsulfonyloxy group.
하기 화학식 (Ⅶ) 화합물의 라세믹 화합물 (Ⅶ') 화합물을 할로겐 화합물과 반응시켜 화합물 (Ⅸ)을 얻고, 얻은 (Ⅸ) 화합물을 하기 화학식 (Ⅷ) 화합물과 유기용매 및 산수용체 존재하 80-140 ℃에서 축합 반응시켜 하기 화학식 (Ⅲ)의 라세믹 화합물을 얻은 다음,The racemic compound (VII ') of the compound of formula (VII) is reacted with a halogen compound to obtain compound (VII), and the obtained compound (VII) is present in the presence of the compound of formula (VII), an organic solvent and an acid acceptor. Condensation reaction at 140 ° C. to obtain a racemic compound of formula (III) 얻어진 (±)-4-[(4-클로로페닐)-2-피리딜 메톡시]피페리딘-1-일-R(Ⅲ) 혼합물을 광학 활성 분리제로 R-(-)-10-캄포설폰산 또는 (-)-디벤조일 타르타릭산을 이용하여 고수율 고순도로 라세믹체 혼합물 중에서 (S)체만을 광학 분리를 한 후, 일반적인 방법으로 보호기 (R)을 제거하는 구조식 (Ⅱ) 화합물의 제조방법.The resulting mixture of (±) -4-[(4-chlorophenyl) -2-pyridylmethoxy] piperidin-1-yl-R (III) as R-(-)-10-camphorsulfur as an optically active separating agent Preparation of Structural Formula (II) Compounds Having Optical Separation of (S) Only in Racemic Mixtures with High Yield High Purity Using Phonic Acid or (-)-Dibenzoyl Tartaric Acid, and then Removing the Protecting Group (R) by a Common Method Way.
Figure 112009060564329-PAT00010
Figure 112009060564329-PAT00010
상기 식에서, R은 아세틸, 벤조일기, 벤질기 등의 아미노 보호기이고, X는 하이드록실기이다.In the above formula, R is an amino protecting group such as acetyl, benzoyl, benzyl group, and X is a hydroxyl group.
KR1020090093724A 2009-10-01 2009-10-01 Process for the preparation of active piperidine compounds by optical isolation Active KR101146009B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020090093724A KR101146009B1 (en) 2009-10-01 2009-10-01 Process for the preparation of active piperidine compounds by optical isolation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020090093724A KR101146009B1 (en) 2009-10-01 2009-10-01 Process for the preparation of active piperidine compounds by optical isolation

Publications (2)

Publication Number Publication Date
KR20110036191A true KR20110036191A (en) 2011-04-07
KR101146009B1 KR101146009B1 (en) 2012-05-15

Family

ID=44044185

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020090093724A Active KR101146009B1 (en) 2009-10-01 2009-10-01 Process for the preparation of active piperidine compounds by optical isolation

Country Status (1)

Country Link
KR (1) KR101146009B1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130324507A1 (en) * 2012-06-05 2013-12-05 Bioprojet Novel (aza)Benzhydryl Ether Derivatives, Their Process of Preparation and Their Use as H4-Receptor Ligands for Therapeutical Applications
WO2019117550A1 (en) * 2017-12-11 2019-06-20 Cj Healthcare Corporation Intermediates for optically active piperidine derivatives and preparation methods thereof
CN113480521A (en) * 2021-07-12 2021-10-08 成都丽凯手性技术有限公司 Total synthesis method of bepotastine besilate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH644012A5 (en) * 1980-01-25 1984-07-13 Schaerer Ag M OPERATING TABLE.
TW486475B (en) 1996-12-26 2002-05-11 Ube Industries Acid addition salt of optically active piperidine compound and process for preparing the same

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130324507A1 (en) * 2012-06-05 2013-12-05 Bioprojet Novel (aza)Benzhydryl Ether Derivatives, Their Process of Preparation and Their Use as H4-Receptor Ligands for Therapeutical Applications
US9242959B2 (en) * 2012-06-05 2016-01-26 Bioprojet (Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
WO2019117550A1 (en) * 2017-12-11 2019-06-20 Cj Healthcare Corporation Intermediates for optically active piperidine derivatives and preparation methods thereof
CN111587240A (en) * 2017-12-11 2020-08-25 怡诺安有限公司 Intermediate of optically active piperidine derivative and process for producing the same
US11254641B2 (en) 2017-12-11 2022-02-22 Hk Inno.N Corporation Intermediates for optically active piperidine derivatives and preparation methods thereof
CN111587240B (en) * 2017-12-11 2023-09-01 怡诺安有限公司 Intermediate of optically active piperidine derivative and process for producing the same
US11780810B2 (en) 2017-12-11 2023-10-10 Hk Inno.N Corporation Intermediates for optically active piperidine derivatives and preparation methods thereof
CN113480521A (en) * 2021-07-12 2021-10-08 成都丽凯手性技术有限公司 Total synthesis method of bepotastine besilate
CN113480521B (en) * 2021-07-12 2024-04-16 成都丽凯手性技术有限公司 Full synthesis method of bepotastine besilate

Also Published As

Publication number Publication date
KR101146009B1 (en) 2012-05-15

Similar Documents

Publication Publication Date Title
US5869657A (en) Preparation of arthropodicidal oxadiazines
US7763730B2 (en) Method preparation clopidogrel and intermediates used therein
KR101146009B1 (en) Process for the preparation of active piperidine compounds by optical isolation
HU213473B (en) Process for preparing flunixin
CH616161A5 (en)
KR101041551B1 (en) New intermediates useful for the preparation of aripiprazole and methods for preparing new intermediates and aripiprazole
FR2562895A1 (en) NOVEL TRIAZOLOPYRIDIMIDINES AND PROCESS FOR THEIR MANUFACTURE
HU201921B (en) New process for producing 6-acylforscholine derivatives
EP0819114B1 (en) An arthropodicidal oxadiazine intermediate
JP2001521498A (en) Method for producing O- (3-amino-2-hydroxy-propyl) -hydroxymic acid halide
KR890001241B1 (en) Process for preparing 4-acetyl isoquinolinone
US4701528A (en) Intermediates useful in the preparation of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates and process for preparing same
KR100699457B1 (en) Method for preparing dibenzothione derivatives and intermediates thereof
KR101154767B1 (en) New process for the preparation of optical active piperidine compounds
FI64136C (en) PROCEDURE FOR FRAMSTATION OF AV D-2- (6-METHOXY-2-NAPHTHYL) -PROPIONSYRA
EP0639558B1 (en) Process for preparation of 1-acyl-2-substituted-hydrazines
JP4973210B2 (en) New synthesis method
CN119798263A (en) A kind of ticagrelor acetyl derivative and preparation method
KR100201582B1 (en) Process for preparing pyrimidyloxy benzoic acid oxime ester derivative having herbicidal activity
JPH10158259A (en) Method for producing 3-alkylflavanonol derivative
JPH07330697A (en) Method for producing substituted indane derivative
JPS6259106B2 (en)
JPS61158962A (en) Production of 1,4-dihydropyridine derivative
JP2003055375A (en) Method for producing optically active hydrazine compound
JPS59128379A (en) Dibenzo(b,f)(1,5)oxazocine derivative and its preparation

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20091001

PA0201 Request for examination
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20100322

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110929

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120416

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120507

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120507

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20150507

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20150507

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20160503

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160503

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180508

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180508

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20190507

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20190507

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20210316

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20220509

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20230508

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20240507

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20250507

Start annual number: 14

End annual number: 14